109P - Epidermal growth factors tyrosine-kinase inhibitors (EGFR-TKI) efficacy in NSCLC patients with high polysomy of chromosome 7 and EGFR/KRAS wild type...

Date 28 March 2014
Event ELCC 2014
Session Lunch and poster display session
Topics Anti-Cancer Agents & Biologic Therapy
Non-Small-Cell Lung Cancer, Metastatic
Presenter Francesca Toffalorio
Citation Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131
Authors F. Toffalorio1, F. Conforti1, G. Spitaleri1, C. Catania1, C. Noberasco1, C. Lazzari1, M. Barberis2, F. de Marinis1, T. De Pas1
  • 1Medical Oncology, European Institute of Oncology, 20141 - Milan/IT
  • 2Pathology Division, European Institute of Oncology, 20141 - Milan/IT


Background: More than even before, the efficacy of epidermal growth factors tyrosine-kinase inhibitors (EGFR-TKI) in NSCLC patients carrying EGFR wild-type tumors has been under investigation. EGFR wild-type patients represent a large and heterogeneous group of patients. In this setting, the role played by high polysomy of chromosome 7 still remains controversial. Indeed, previous reports did not discriminate between chromosome 7 high polysomy and EGFR amplification and/or did not investigate the simultaneous presence of EGFR and KRas mutations.